Estland - estniska - Ravimiamet

sandoz pharmaceuticals d.d. - sertraliin - õhukese polümeerikattega tablett - 50mg 28tk

Estland - estniska - Ravimiamet

lex ano uab - sertraliin - õhukese polümeerikattega tablett - 50mg 28tk

Estland - estniska - Ravimiamet

ideal trade links uab - sertraliin - õhukese polümeerikattega tablett - 100mg 28tk; 100mg 14tk

Estland - estniska - Ravimiamet

rivopharm limited - sertraliin - õhukese polümeerikattega tablett - 100mg 100tk; 100mg 20tk; 100mg 50tk; 100mg 42tk; 100mg 98tk; 100mg 28tk

Estland - estniska - Ravimiamet

rivopharm limited - sertraliin - õhukese polümeerikattega tablett - 50mg 14tk; 50mg 98tk; 50mg 20tk; 50mg 42tk; 50mg 28tk; 50mg 100tk; 50mg 30tk

Europeiska unionen - estniska - EMA (European Medicines Agency)

oncopeptides ab - melphalan flufenamide hydrochloride - mitu müeloomit - antineoplastilised ained - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.

Europeiska unionen - estniska - EMA (European Medicines Agency)

adienne s.r.l. s.u. - melphalan hydrochloride - multiple myeloma; hodgkin disease; lymphoma, non-hodgkin; precursor cell lymphoblastic leukemia-lymphoma; leukemia, myeloid, acute; neuroblastoma; ovarian neoplasms; hematopoietic stem cell transplantation - antineoplastilised ained - high-dose of phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (hodgkin, non-hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma. phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (ric) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-hsct) in malignant haematological diseases in adults. phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:myeloablative conditioning (mac) treatment in case of malignant haematological diseasesric treatment in case of non-malignant haematological diseases.

Europeiska unionen - estniska - EMA (European Medicines Agency)

les laboratoires servier - irinotecan anhydrous free-base - pankrease neoplasmid - antineoplastilised ained - metastaatilise ravi, koos 5-fluorouratsiili (5-fu) ja leukovoriiniga (lv), täiskasvanud patsientidel, kelle haigus pärast gemtsitabiini ravi põhineb ravi.

Europeiska unionen - estniska - EMA (European Medicines Agency)

accord healthcare s.l.u. - buprenorphine hydrochloride, naloxone hydrochloride dihydrate - opioidiga seotud häired - muud närvisüsteemi ravimid - opioidide ravivastuse asendusravi meditsiinilise, sotsiaalse ja psühholoogilise ravi raamistikus. naloksooni komponendi eesmärk on ära hoida intravenoosset väärkasutamist. ravi on ette nähtud kasutamiseks täiskasvanutel ja üle 15-aastastel noorukitel, kes on nõustunud sõltuvuse raviks.

Estland - estniska - Ravimiamet

dne pharma as - levometadoon - suukaudne lahus üheannuselises konteineris - 75mg 7tk; 75mg 1tk